Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renee Hukkanen

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Toxicologic Pathology|August 16, 2024
A Developmental Atlas as a Reflection of Our Professional LifecycleRenee Hukkanen
Toxicologic Pathology|November 18, 2025
STP Town Hall Discussion on the Use of Virtual Control Groups in Nonclinical Toxicity StudiesKirstin Barnhart, Brad Bolon, Laura Boone, et al.
Toxicologic Pathology|December 11, 2024
Session 5: Protein DegradersKiran Palyada, Renee Hukkanen, Stephanie Leuenroth-Quinn, et al.
Regulatory Toxicology and Pharmacology : RTP|February 27, 2025
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to considerLise I Loberg, William R Proctor, Andrew D Burdick, et al.
Molecular Cancer Therapeutics|March 21, 2022
Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chanda, Shannon McGrath, et al.
Molecular Cancer Therapeutics|April 3, 2023
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chandra, Shannon McGrath, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Toxicologic Pathology|August 16, 2024
A Developmental Atlas as a Reflection of Our Professional LifecycleRenee Hukkanen
Toxicologic Pathology|November 18, 2025
STP Town Hall Discussion on the Use of Virtual Control Groups in Nonclinical Toxicity StudiesKirstin Barnhart, Brad Bolon, Laura Boone, et al.
Toxicologic Pathology|December 11, 2024
Session 5: Protein DegradersKiran Palyada, Renee Hukkanen, Stephanie Leuenroth-Quinn, et al.
Regulatory Toxicology and Pharmacology : RTP|February 27, 2025
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to considerLise I Loberg, William R Proctor, Andrew D Burdick, et al.
Molecular Cancer Therapeutics|March 21, 2022
Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chanda, Shannon McGrath, et al.
Molecular Cancer Therapeutics|April 3, 2023
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chandra, Shannon McGrath, et al.
Pageof 1